These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3177533)

  • 1. Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors.
    Haisma HJ; Moseley KR; Battaile A; Griffiths TC; Knapp RC
    Am J Obstet Gynecol; 1988 Oct; 159(4):843-8. PubMed ID: 3177533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution, pharmacokinetics and imaging of 131I-labelled OC125 in ovarian cancer.
    Haisma HJ; Moseley KR; Battaile AI; Griffiths TC; Zurawski VR; Knapp RC
    Int J Cancer Suppl; 1988; 2():109-13. PubMed ID: 3162437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of indium-111-labeled OC 125 monoclonal antibody after intraperitoneal injection in nude mice intraperitoneally grafted with ovarian carcinoma.
    Thédrez P; Saccavini JC; Nolibé D; Simoen JP; Guerreau D; Gestin JF; Kremer M; Chatal JF
    Cancer Res; 1989 Jun; 49(11):3081-6. PubMed ID: 2720666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration.
    Ward BG; Mather SJ; Hawkins LR; Crowther ME; Shepherd JH; Granowska M; Britton KE; Slevin ML
    Cancer Res; 1987 Sep; 47(17):4719-23. PubMed ID: 3621168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.
    Chatal JF; Saccavini JC; Gestin JF; Thédrez P; Curtet C; Kremer M; Guerreau D; Nolibé D; Fumoleau P; Guillard Y
    Cancer Res; 1989 Jun; 49(11):3087-94. PubMed ID: 2720667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model.
    Kairemo K; Ljunggren K; Strand SE; Hiltunen J; Penttilä P; Nikula T; Laine A; Wahlström T
    Acta Oncol; 1993; 32(7-8):801-5. PubMed ID: 8305229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125.
    Muto MG; Lepisto EM; Van den Abbeele AD; Knapp RC; Kassis AI
    Am J Obstet Gynecol; 1989 Nov; 161(5):1206-12. PubMed ID: 2686446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.
    Muto MG; Finkler NJ; Kassis AI; Howes AE; Anderson LL; Lau CC; Zurawski VR; Weadock K; Tumeh SS; Lavin P
    Gynecol Oncol; 1992 Jun; 45(3):265-72. PubMed ID: 1612502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration.
    Rosenblum MG; Kavanagh JJ; Burke TW; Wharton JT; Cunningham JE; Shanken LJ; Silva EG; Thompson L; Cheung L; Lamki L
    J Natl Cancer Inst; 1991 Nov; 83(22):1629-36. PubMed ID: 1721093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage.
    Wahl RL; Barrett J; Geatti O; Liebert M; Wilson BS; Fisher S; Wagner JG
    Cancer Immunol Immunother; 1988; 26(3):187-201. PubMed ID: 3383203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.
    Buist MR; Kenemans P; den Hollander W; Vermorken JB; Molthoff CJ; Burger CW; Helmerhorst TJ; Baak JP; Roos JC
    Cancer Res; 1993 Nov; 53(22):5413-8. PubMed ID: 8221680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration.
    Buijs WC; Tibben JG; Boerman OC; Molthoff CF; Massuger LF; Koenders EB; Schijf CP; Siegel JA; Corstens FH
    Eur J Nucl Med; 1998 Nov; 25(11):1552-61. PubMed ID: 9799353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
    Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
    Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab')2 in experimental ovarian cancer.
    Tibben JG; Massuger LF; Boerman OC; Borm GF; Claessens RA; Corstens FH
    Eur J Nucl Med; 1994 Nov; 21(11):1183-90. PubMed ID: 7859769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125.
    Muto MG; Finkler NJ; Kassis AI; Lepisto EM; Knapp RC
    Gynecol Oncol; 1990 Aug; 38(2):244-8. PubMed ID: 2387541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies.
    Malamitsi J; Skarlos D; Fotiou S; Papakostas P; Aravantinos G; Vassilarou D; Taylor-Papadimitriou J; Koutoulidis K; Hooker G; Snook D
    J Nucl Med; 1988 Dec; 29(12):1910-5. PubMed ID: 3193206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoscintigraphy of recurrences of gynecologic carcinomas.
    Chatal JF; Fumoleau P; Saccavini JC; Thedrez P; Curtet C; Bianco-Arco A; Chetanneau A; Peltier P; Kremer M; Guillard Y
    J Nucl Med; 1987 Dec; 28(12):1807-19. PubMed ID: 3500284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.